Introduction

The novel beta-coronavirus SARS-CoV-2 infection (COVID-19), that emerged in December 2019, has generated a global crisis. As of April 2021, over 140 million people have been infected with SARS-CoV-2, of which nearly 3 million people have died¹. In Mexico over 2.3 million people have been infected and more than 216,000 deaths have been reported, being one of the countries with the highest COVID-19 death tolls worldwide, behind Brazil and The United States of America².

Severe cases in susceptible patients have been associated with the development of a condition called “cytokine storm” in response to SARS-CoV-2 antigens³. Cytokine storm consists of a deregulated immune response with excessive production and release of interleukin (IL)-1, IL-8 and IFN-γ, leading to hemodynamic compromise and multiple organ failure^4,5. The reason why some patients are more susceptible to developing severe disease has not been fully elucidated. According to clinical and basic research, factors such as older age, being male, and comorbidities like type 2 diabetes, obesity, hypertension, asthma, chronic obstructive pulmonary disease (COPD), or cancer have been associated with more severe disease and increased mortality in patients with COVID-19^6,7,8

It is necessary to find prognosis factors for patients hospitalized with SARS-CoV-2 to identify patients with increased mortality-risk and help manage hospital occupancy more efficiently. Furthermore, the knowledge of these factors could help to understand the mechanisms that lead to severity observed in patients with common characteristics. Besides the factors mentioned above, there has been an increasing interest in the relationship between the ABO blood group system and COVID-19 severity. Several studies have shown that polymorphisms within the ABO gene are associated with different traits, including risk factors for COVID-19 mortality. For instance, variants of ABO groups have been linked to diseases like gastric cancer, myocardial infarction, type 2 diabetes, and venous thromboembolism⁹.

The relation between ABO groups and morbidity and mortality in viral infections has been well documented. The findings of Liao (2020) suggest that individuals with blood group O may be more susceptible to norovirus infection, although these individuals appear to be less susceptible to SARS-CoV-1 and Norwalk infection^10,11. Increased susceptibility to rotavirus gastroenteritis and smallpox have been observed for blood group A and groups A and AB, respectively¹². Furthermore, there is evidence suggesting an increased risk of developing severe viral illness according to an individual’s blood group; for instance, group AB has been associated with 2.5 greater risk of developing severe dengue infection¹¹.

There is enough evidence to support the hypothesis that patients with blood group A are more likely to have SARS-CoV-2 infection compared with group O. Gollineli (2020) found through a meta-analysis that COVID-19-positive individuals are more likely to have blood group A (pooled OR 1.23, 95% IC 1.09-1.4) compared with blood group O (pooled OR 0.77 95% IC 0.67-0.88). Some claims have been made about the possible explanation of this relationship, including the modulation of angiotensin-converting enzyme 2 (ACE2) expression by the ABO blood group locus and the possible cross-reactivity of SARS-CoV-2 antigens with blood group O natural anti-A and anti-B antibodies^13,14.

Regarding the association of ABO blood groups with COVID-19 mortality, early reports from Wuhan found that group O was linked with a higher risk of COVID-19 severity and mortality compared with group A. In a meta-analysis by Wu (2020) including predominantly Chinese populations, no association between ABO blood groups and COVID-19 severity and mortality was found¹⁵. However, studies carried out in other countries have shown contradictory results, proposing a more complex relation between ABO blood groups and COVID-19 mortality. For example, a study from the United States with 14,112 confirmed SARS-CoV-2 patients found a decreased risk of death and intubation in patients with group A relative to group O⁹.

Latin-American studies of ABO blood groups and COVID-19 are scarce, based on small samples and not adjusted for other variables; thus, the relationship between COVID-19 and in-hospital mortality has not been reported in Mexican populations. The aim of this paper is to explore the association between ABO blood groups and in-hospital mortality in Mexican patients admitted with COVID-19.

Materials and Methods

We performed a retrospective study with 2,369 hospitalized patients with confirmed SARS-CoV-2 infection in a tertiary referral hospital in Mexico City, Mexico (Central Military Hospital [CMH], from the National Secretariat of Defense [SEDENA, for its acronym in Spanish]). SARS-CoV-2 infection was confirmed using real-time reverse transcription polymerase chain reaction (RT-PCR) from a nasopharyngeal swab. Epidemiological data including age, sex, blood group and comorbidities were obtained from electronic health records (Digital Health System) of the CMH. We included all patients with confirmed SARS-CoV-2 infection who either died or were discharged between March 27 and December 10, 2020. ABO groups and Rh types were determined through agglutination techniques by a clinical laboratory affiliated to SEDENA when patients were first included in the Digital Heath System. Patients with incomplete data were excluded.

Data are presented as mean (standard deviation [SD]) and counts (percentage) for numerical and categorical variables, respectively. Two groups were formed according to one of two outcomes: death or discharge. Categorical variables were compared using the Chi-square test or Fisher’s exact test, and continuous variables were compared using an unpaired t-test. Survival curves stratified according to ABO blood group were estimated using the Kaplan-Meier method, and curves were compared using the Breslow test. A multivariate Cox proportional hazard regression was performed to identify variables independently associated with COVID-19 death during hospitalization. Hazard Ratios (HR) were estimated as a measure of effect size of the variables included in the Cox regression. We fitted the following saturated model:

Where ln(λt ) is the natural logarithm of the hazard at time t, and ln(λ0t) is the natural logarithm of the baseline hazard. We checked the proportional hazard assumption for categorical variables by using the graph of the log(-log(survival)) versus survival time. We determined adjusted and unadjusted odds ratios (OR) from logistic regression models to predict COVID-19 mortality. We checked the goodness of fit of logistic models with the Hosmer-Lemeshow test. The saturated logistic model included the same variables as the saturated Cox model. P values <0.05 were considered as statistically significant. All analyses were performed with IBM Statistics SPSS 21, whereas bar graphs and forest plots were elaborated in GraphPad Prism 8.4.0.

This study was approved by the research committee at the Central Military Hospital with registration number 066/2020. The present study complied with the basic principles of human research following the Helsinki Declaration of the Medical Association. The data collected was handled confidentially.

Results

A total 2,369 patients were evaluated; 1,685 (71.1%) patients were discharged, and 684 (28.8%) patients died during hospitalization. Most patients were male 1478 (62.3%). The mean age was 53.5 years (SD 16). The most frequent comorbidities were type 2 diabetes (DM) (14.8%), hypertension (14.5%) and obesity (11.4%). Non-survivor patients were older with a mean age of 63 (SD 14.1). Most patients were male, compared with the survivor group (67% vs 60%) (P = 0.003). The most frequent comorbidities among non-survivor patients were hypertension (22.1%), DM (14.8%), and obesity (17.3%). Of the total population, 574 (24.2%) were active military personnel.

Group O was the most prevalent group in 1,999 patients (84.3%); the distribution of ABO groups is shown in Figure 1. Distribution of ABO blood groups in discharged and deceased patients are presented in Figure 2. A total 2,330 (98.3%) patients were Rh-positive among the total population. Epidemiological features of these groups are listed in Table 1. Compared with discharged patients, the percentage of blood group O was significantly higher in patients who died (83.3% vs 87%) (P < 0.001), whereas the percentage of patients with blood group A was significantly lower (12.3% vs 8.88%) (P < 0.001). Kaplan-Meier curves are shown in Figure 3; survival for different ABO blood groups were significantly different (P = 0.02).

Adjusted and unadjusted Cox model analyses are presented in Table 1. Unadjusted and adjusted odds ratios of risk factors for COVID-19 mortality are shown in Table 2. A Forest Plot of the hazard ratios of death for ABO blood groups is presented in Figure 4.

In summary, blood group A had a significant lower risk of death compared with group O (adjusted HR = 0.72, 95% IC 0.55-0.95, P = 0.02). Groups B, AB and Rh-positive were not significantly associated with the outcome. Moreover, type 2 diabetes (adjusted HR 1.54, 95% IC 1.27-1.88, P < 0.001) and obesity (adjusted HR 1.95 95% IC 1.6-2.39 P <0.001) were statistically significantly associated with an increased risk of death by COVID-19. Hypertension showed not statistical significance with respect to mortality in the adjusted model (adjusted HR 0.87, 95% IC 0.7-1.06 P <0.8), despite being associated with mortality in the unadjusted model (unadjusted HR 1.76 1.95% IC 1.47-2.11 P <0.001).

Discussion

Mexico has been one of the most affected countries by COVID-19 worldwide as reflected by the death-toll in hospitalized patients. Therefore, identifying in-patient mortality-associated factors in the Mexican population is of utter importance¹. The main results of this study include a statistically significant difference in mortality of COVID-19 patients according to their ABO blood type. Additionally, obesity was the comorbidity with the greatest impact in mortality of the studied population.

In the Central Military Hospital, the three most frequent comorbidities in non-survivors were the same as those reported in other studies of Mexican patients, however, their order of prevalence differed ^16,17.Vera-Zertuche (2021) reported that the three main comorbidities present in non-survivors were hypertension (43%), type 2 diabetes (38%), and obesity (30.5%); the lower prevalence of these comorbidities in our study could be attributable to a lower risk of metabolic diseases in 33% of our population who were active military personnel with an active lifestyle due to their military enadeavors¹⁸. Thus, comorbidities do not fully explain the high risk of developing severe COVID-19 and death in apparently healthy patients in whom other characteristics could be responsible for favoring disease progression and death.

Several reports have identified genetic mechanisms which are strongly heritable that increase susceptibility to severe SARS-CoV-2 infection. These mechanisms are related to innate antiviral defenses and host inflammatory lung response¹⁹. Innate antiviral defense activation is important early during disease and signaling by interferons is essential for response to viral infection. Damage in the interferon receptor subunit 2 (IFNAR2) is associated with severe COVID-19^19,20. Furthermore, decreased expression of the interferon-inducible oligoadenylate synthase gene cluster (OAS) has been implicated in susceptibility to SARS-CoV-2²¹. The mechanisms involved in lung inflammation are linked to the late complications of the disease. One of the most important mechanisms involved is the over-expression of CC-chemokine-receptor 2, which promotes chemotaxis of monocytes-macrophages to sites of inflammation, thereby increasing damage due to the inflammatory response²².

After multivariate adjustment, obesity was the comorbidity with the highest impact on mortality in our study; type 2 diabetes, older age, and male gender were also associated with mortality, similar toother observational studies^19,23,24. Mechanisms of susceptibility to COVID-19 in obesity have not been fully characterized; preliminary studies mention the role of chronic inflammation, metabolic dysfunction, deficiency of vitamin D, gut microbiota dysbiosis and over-expression of ACE2 protein as factors that could explain increased mortality²⁵. Regarding patients with diabetes, impaired phagocyte cell capabilities, over-expression of Furin and ACE-2 receptor and altered function of T-cells could be involved²⁶. The worst prognosis reported in elderly patients could be due to the many chronic diseases seen in this population and the dysregulation of lymphoid organs; it has also been found that DPP4 enzymatic expression is higher in elderly people. SARS-CoV-2 uses DPP4 to enter cells and its upregulation has been reported in patients with severe disease²⁷. The lower risk of developing severe COVID-19 women could be attributed to their ability to mount more robust innate antiviral responses than males²⁸.

We found evidence that blood group A was associated with a lower hazard of death among COVID-19 patients (Unadjusted HR = 0.71 IC 0.54-0.92), whilst a higher risk of death was found for group O. Moreover, the association between mortality and blood group in the univariate analysis was quite similar when the Cox model was adjusted for the main risk factors that influence COVID-19 mortality in the Mexican^16-18. In the adjusted model, blood group A kept the lower hazard of death compared with group O (Adjusted HR = 0.72, 95% IC 0.55-0.95). Groups B and AB do not appear to be associated with the studied clinical outcomes. In both the univariate and multivariate analyses, the measures of effect size OR and HR showed the same associations between risk factors and COVID-19 mortality. Interestingly, we obtained very similar adjusted HR and adjusted OR estimates for risk factors when a subgroup analysis was performed excluding active military personnel (Data not shown).

There are only few studies comparable to ours performed in hospitalized populations. Yet, our findings match those of studies carried in Saudi Arabia and Egypt²⁹ (Group O was associated with higher intubation rates compared with group A) and USA (patients with blood Group A had a lower risk of intubation and death compared with groups AB and O).. Nonetheless, our results contradict those of studies carried out in France, Iraq, and Canada in which group A conferred a higher mortality risk, and those from Denmark and China in which no association was found between ABO groups and death^29,15.

Severe and critical COVID-19 have been associated with a pathological state characterized by rapid and prolonged systemic elevation of cytokines and chemokines named “cytokine storm”. Several studies have linked the cytokine storm with tissue injury, multiple organ failure and death³⁰. The increased mortality risk of patients with blood type O observed in our study could be explained by the evidence that suggests that these patients have increased IL-6 and IL-10 levels compared with patients with other blood types. High levels of IL-6 have been reported in patients infected with Helicobacter pylori and a genome-wide association study reported increased susceptibility of group O cells to release more IL-10³¹. Moreover, another study reported that patients with blood group O had higher levels of IL-10 in response to acute coronary syndrome³². Even though IL-10 was thought to suppress inflammation, new evidence suggests that early dramatic elevation of IL-10 may play a pathological role in COVID-19³³.

The controversy across reports could be explained by genetic variations among patients with the same blood type and the traits associated with different blood types which could be developed only under certain lifestyle circumstances such as hypertension in people with blood group O³⁴. Furthermore, the relationship between ABO blood groups and mortality could be more complex, and certain lifestyles or genetic conditions in distinct populations could synergize with certain blood groups to favor a deregulated immune system with greater risk of developing a life-threatening COVID-19 scenario.

Limitations of this study are those inherent to retrospective studies. Secondly, the population consisted only of Mexicans receiving medical care in Mexico City; therefore, our results cannot be generalized to other populations. Thirdly, we had insufficient data to estimate indicators of COVID-19 severity rates.

In conclusion, we found evidence of a significant association between ABO blood type and COVID-19 in-patient death. Blood group A may be less likely to experience death during hospitalization compared with group O. There were no significant associations between blood groups AB and B with the risk of COVID-19 death.

Acknowledgments

We express our gratitude to all the staff of the Central Military Hospital - SEDENA for their work during the COVID-19 health contingency. The authors are grateful to Dr. Julian Torres Vázquez for his logistical support during the study.

References

1. COVID-19 United States Cases by County - Johns Hopkins Coronavirus Resource Center [Internet]. [cited 2021 Feb 20]. Available from: https://coronavirus.jhu.edu/us-map

2. Mortality Analyses - Johns Hopkins Coronavirus Resource Center [Internet]. [cited 2021 Apr 29]. Available from: https://coronavirus.jhu.edu/data/mortality

3. Ruscitti P, Berardicurti O, Iagnocco A, et al. Cytokine storm syndrome in severe COVID-19. Autoimmun Rev. 2020;19(7):102562. Available from https://doi.org/10.1016/j.autrev.2020.102562

4. Ombrello M, Schulert G. COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome? Transl Res. 2021: S1931-5244(21)00052-9 Available from: https://doi.org/10.1016/j.trsl.2021.03.002

5. Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020 ;13(12):1833-1839. Available from: https://doi.org/10.1016/j.jiph.2020.07.014

6. Haitao T, Vermunt JV, Abeykoon J, et al. COVID-19 and Sex Differences: Mechanisms and Biomarkers. Mayo Clin Proc. 2020 ;95(10):2189-2203. Available from: https://doi.org/10.1016/j.mayocp.2020.07.024

7. Mueller A, McNamara M, Sinclair D. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020 ;12(10):9959-9981. Available from: https://doi.org/10.18632/aging.103344

8. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708–20. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2002032

9. Zietz M, Zucker J, Tatonetti N. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020 Dec 1;11(1):1–6. Available from: https://doi.org/10.1038/s41467-020-19623-x

10. Liao Y, Que L, Gao J, et al. ABO blood group-associated susceptibility to norovirus infection: A systematic review and meta-analysis. Infect Genet Evol. 2020 Jul ; 81:104245. Available from: https://doi.org/10.1016/j.meegid.2020.104245

11. Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. Blood Transfus. 2021 May 12. Available from: https://doi.org/10.2450/2021.0049-21

12. Garratty G. Relationship of blood groups to disease: do blood group antigens have a biological role? Rev Med Inst Mex Seguro Soc. 2005;43(Suppl: 1):113-121. Available from: https://www.medigraphic.com/pdfs/imss/im-2005/ims051ab.pdf

13. Golinelli D, Boetto E, Maietti E, The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. PLoS One. 2020 Sep 18;15(9): e0239508. Available from: https://doi.org/10.1371/journal.pone.0239508

14. Zhang Y, Garner R, Salehi S, La Rocca M, Duncan D. Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies. Ann Hematol. 2021 May;100(5):1123-1132. Available from: https://doi.org/10.1007/s00277-021-04489-w

15 Wu B, Gu D, Yu J, Yang J, Shen W. Association between ABO blood groups and COVID-19 infection, severity, and demise: A systematic review and meta-analysis. Infect Genet Evol. 2020 Oct;84:104485. Available from: https://doi.org/10.1016/j.meegid.2020.104485

16. Nájera H, Ortega-Ávila A. Health and Institutional Risk Factors of COVID-19 Mortality in Mexico, 2020. Am J Prev Med. 2021; 60(4):471–7. Available from: https://doi.org/10.1016/j.amepre.2020.10.015

17. Escobedo-de-la-Peña J, Rascón-Pacheco R, Ascencio-Montiel I, et al. Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients With COVID-19 in Mexico. Arch Med Res. 2020; S0188-4409(20)32243-8 Available from: https://doi.org/10.1016/j.arcmed.2020.12.002

18. Vera-Zertuche J, Mancilla-Galindo J, Tlalpa-Prisco M, et al. Obesity is a strong independent risk factor for short-term mortality and adverse outcomes in Mexican patients with COVID-19: A national observational study. Epidemiology and Infection. 2021; 1-45. Available from: https://doi.org/10.1017/S0950268821001023

19. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021 ;591(7848):92-98. Available from: https://doi.org/10.1038/s41586-020-03065-y

20. Zhang Q, Bastard P, Liu Z et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 ;370(6515): eabd4570. Available from: https://www.doi.org/10.1126/science.abd4570

21. He J, Feng D, de Vlas S, et al. Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study. BMC Infect Dis. 2006; 6:106. Available from: https://doi.org/10.1186/1471-2334-6-106

22. Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight. 2020;5(13): e139834. Available from: https://www.doi.org/10.1172/jci.insight.139834

23. Gérard C, Maggipinto G, Minon J. COVID‐19 and ABO blood group: another viewpoint. Br J Haematol. 2020 ;190(2): e93–4. Available from: https://doi.org/10.1111/bjh.16884

24. Hoiland R, Fergusson N, Mitra A, et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv. 2020 ;4(20):4981–9. Available from: https://doi.org/10.1182/bloodadvances.2020002623

25. Petrova D, Salamanca-Fernández E, Rodríguez Barranco M, et al. La obesidad como factor de riesgo en personas con COVID-19: posibles mecanismos e implicaciones. Aten Primaria. 2020 ;52(7):496-500 Available from: https://doi.org/10.1016/j.aprim.2020.05.003

26. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. Available from: https://www.doi.org/10.1001/jama.2020.1585

27. Bajaj V, Gadi N, Spihlman A, et al. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front Physiol. 2021; 11:571416. Available from: https://doi.org/10.3389/fphys.2020.571416

28. Pradhan A, Olsson P. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020 Sep 18;11(1):53. Available from: https://doi.org/10.1186/s13293-020-00330-7

29. El-Shitany N, El-Hamamsy M, Alahmadi A, et al. The Impact of ABO Blood Grouping on COVID-19 Vulnerability and Seriousness: A Retrospective Cross-Sectional Controlled Study among the Arab Community. Int. J. Environ. Res Public Health. 2021 ;18(1):276. Available from: https://doi.org/10.3390/ijerph18010276

30. Tay M, Poh C, Rénia L, et al. The trinity of COVID-19: immunity, inflammation, and intervention. Nat Rev Immunol. 2020 ;20(6):363–74. Available from: https://doi.org/10.1038/s41577-020-0311-8

31. Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect, 2020 ;9(1):1123–30. Available from: https://doi.org/10.1080/22221751.2020.1770129

32. Johansson Å, Alfredsson J, Eriksson, et al. Genome-wide association study identifies that the ABO blood group system influences interleukin-10 levels and the risk of clinical events in patients with acute coronary syndrome. PLoS ONE. 2015 ;10(11): e0142518. Available from: https://doi.org/10.1371/journal.pone.0142518

33. Lu L, Zhang H, Dauphars D, et al. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. Trends Immunol. 2021 ;42(1):3-5. Available from: https://doi.org/10.1016/j.it.2020.10.012

34. Naitza S, Porcu E, Steri M, et al. A genome-wide association scan on the levels of markers of inflammation in sardinians reveals associations that underpin its complex regulation. PLoS Genet. 2012 ;8(1). Available from: https://doi.org/10.1371/journal.pgen.1002480.

Información adicional

Conflicts of Interest: The authors declare no conflicts of interest

Authors contribution: Conceptualization and design, C.V.DL. and M.U.V.M; Methodology, C.V.DL. and M.U.V.M; Data acquisition and software, E.C.R, C.A.B.C. and J.A.A.F.; Data curation, analysis and interpretation, M.U.V.M, C.V.DL. and E.C.R.; Principal investigator, C.V.DL.; Investigation, M.U.V.M, C.A.B.C. and J.A.A.F.; Manuscript writing-Preparation of original draft, M.U.V.M; Writing, review and editing of manuscript, C.V.DL., M.U.V.M., E.C.R. and M.E.O.H.; Visualization, C.V.DL. and M.E.O.H.; Supervision, C.V.DL. and E.C.R.; Acquisition of funds, Not applicable